Alessandro earned a BSc in Biotechnology from the University of Trento and a MSc in Pharmaceutical Biotechnology from the University of Bologna. In 2023, he relocated to the UK to join bit.bio, a Cambridge-based company specialised in products derived from the efficient programming of iPSCs into mature cell types using proprietary Opti-OX™ technology. Alessandro joined Dr Sreedharan's Lab in August 2025 and will contribute to investigating the role of SCFD1 and G2E3 in MND, exploring their potential as therapeutic targets. This is a Darby Rimmer Foundation funded project in partnership with Prof. Alfredo Iacoangeli in the Department of Biostatistics.

Dr Akcay received his PhD from ETH Zurich, studying quantitative genetics of starvation resistance in fruit flies.  After two post-doctoral terms, working on cancer genetics, cancer cell signalling, and monogenic diabetes, he switched to neuroscience by joining Dr Sreedharan’s lab in July 2023. Here, he is investigating the effects of ALS-associated variants in TARDBP and CFAP410 genes on the cellular phenotypes of iPSC-derived neurons and microglia.

Leon studied Biology at the University of York before completing an MSc in Translational Neuroscience at Imperial College London, and started his PhD at the Sreedharan lab in October 2022. During his PhD, he will be utilising CRISPR to manipulate a heterozygous M337V TARDBP mutation in a patient iPSC line. Additionally, in collaboration with Omer Bayrakter (Wellcome Sanger Institute), he will be using spatial transcriptomics to explore cell-type specific molecular changes across different brain regions in the TARDBP Q331K knock-in mouse model.

Aleks obtained her BSc (Hons) in Neuroscience from University College Dublin (UCD), Ireland, before completing an MRes at the University of Edinburgh. In 2019 she moved to King's, working on a gene therapy project in Prof. Chris Shaw’s group before joining the BRAIN Pre-clinical Neuroimaging Centre. She started her PhD in the Sreedharan lab in June 2023, investigating the role of N-terminal splice variants of tau and inhibitory interneuronal network dysfunction in ALS-FTD using TDP-43 knock-in mouse models and ultrastructural histological/ imaging techniques.

Dulcie graduated from Queen’s University Belfast in 2020 with a BSc in Biological Sciences. Since then, she has been developing her molecular biology skills by working on genetically engineering tropical crops to improve yield and sustainability. She joined the Sreedharan lab as a research assistant and is involved in generating novel iPSC lines through CRISPR.

In the Sreedharan lab, Vaishnavi is interested in looking at the effect of variants in the non-coding region of the TARDBP gene on ALS/FTD pathology. Her project uses an amazing CRISPR-based technique called GenIE, to screen for over 100 TDP variants for their influence on TDP-43 gene expression, using iPSC derived cell models. Vaishnavi has previously worked on a screening project in flies during her master's project at the National Centre for Biological Sciences (NCBS), Bangalore.

Dr Mech completed her undergraduate degree in Biotechnology at University of Gdansk and her master's degree in Genetics of Human Disease at UCL. During her PhD in Prof. Caroline Brennan's lab at Queen Mary University of London, she used zebrafish to identify novel genetic variants associated with nicotine addiction. Her work in Dr Sreedharan's lab involves generating CRISPR/Cas9 iPSC lines with mutations associated with ALS.

Sara graduated with an integrated MSc (MSci) in Neuroscience from King’s College London in 2020; where she conducted her BSc project in Prof. Carmine Pariante’s lab and then joined Prof. Chris Miller’s lab investigating ER-mitochondria contacts in Sigma-1-associated ALS. Having worked in the Sreedharan lab for a year developing a screening assay to identify modifiers of TDP-43 autoregulation, she has now started her PhD in which she will be investigating the role of heterogeneous ribonucleoproteins (hnRNPs) in neurodevelopment and neurodegeneration using iPSC-derived models and CRISPR/gene-editing techniques.

During his scientific training, Dr Prajapati acquired interdisciplinary research experiences. After obtaining his PhD in the field of protein folding and thermodynamics, he developed an interest in understanding transcriptional regulation of cell fate decisions, and he worked with Dr David Ish-horowicz (Cancer Research UK), Dr Nicole Fracis (Harvard University) and Andrea Streit (King's College London). Presently, he is dissecting the molecular mechanisms of TDP-43 autoregulation in ALS using proteogenomics.